This benefit, however, may be related to the association between SSTR2A and oligodendrogliomas and their favourable outcome since no significant difference in OS (p = 0.383) or PFS (p = 0.272) was observed within IDH-mutant and IDH-wildtype astrocytomas according to SSTR2A status. The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).